Prevention of Recurrent Staphylococcal Skin Infections With Low-Dose Oral Clindamycin Therapy
Clicks: 62
ID: 112461
1988
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
1.5
/100
5 views
5 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
We conducted a double-blind, controlled trial of low-dose (150 mg/d) oral clindamycin hydrochloride vs placebo to prevent recurrent staphylococcal skin infections. Twenty-two patients (11 in both the placebo and clindamycin treatment groups) completed the trial and were assessable. The two groups did not differ as to age, sex, race, or...
| Reference Key |
klempner1988jamaprevention
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mark S. Klempner;Barbara Styrt; |
| Journal | JAMA |
| Year | 1988 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Administration
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
adult
female
male
aged
middle aged
Recurrence
Clinical Trial
Randomized Controlled Trial
Double-Blind Method
Random Allocation
neutrophils / physiology
oral
staphylococcal skin infections / prevention & control*
pmid:3184334
m s klempner
b styrt
clindamycin / therapeutic use*
staphylococcal skin infections / drug therapy
staphylococcal skin infections / immunology
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.